<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02117934</url>
  </required_header>
  <id_info>
    <org_study_id>DV2-HBV-23</org_study_id>
    <nct_id>NCT02117934</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine</brief_title>
  <official_title>A Phase 3, Observer-Blinded, Randomized, Active-Controlled (Engerix-B), Multicenter Trial of the Safety and Immunogenicity of HEPLISAV in Adults 18 to 70 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dynavax Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dynavax Technologies Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and immunogenicity of an investigational
      hepatitis B vaccine (HEPLISAV) in adults 18 to 70 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of Special Interest</measure>
    <time_frame>Week 56</time_frame>
    <description>The percentage of participants with Medically-attended adverse events (MAEs), Serious Adverse Events (SAEs), and immune-mediated Adverse Events of Special Interest (AESIs). MAEs are Adverse events (AEs) for which a subject sought medical attention at a doctor's office, clinic or study site, or emergency room, or was hospitalized. SAEs are AEs that met the definition of Serious per FDA regulations. Immune-mediated AESIs are AEs that were confirmed to be autoimmune in etiology.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With Type 2 Diabetes Mellitus Who Have a Seroprotective Immune Response</measure>
    <time_frame>Week 28</time_frame>
    <description>Percentage of subjects with type 2 diabetes mellitus who have a seroprotective immune response (anti-HBs ≥ 10 milli-international unit (mIU)/mL) who receive HEPLISAV compared with subjects who receive Engerix-B</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8374</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>HEPLISAV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and placebo (saline injection) at Week 24, followed by a 52-week safety follow-up from the last active dose of HEPLISAV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Engerix-B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.0 mL Engerix-B (20 mcg HBsAg adsorbed on 500 mcg of aluminum hydroxide) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and 24, followed by a 32-week safety follow-up from the last dose of Engerix-B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HEPLISAV</intervention_name>
    <description>Intramuscular injections at Week 0 and Week 4, plus a placebo injection at Week 24</description>
    <arm_group_label>HEPLISAV</arm_group_label>
    <other_name>Hepatitis B vaccine (recombinant), adjuvanted</other_name>
    <other_name>HEPLISAV-B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix-B</intervention_name>
    <description>Intramuscular injections at Week 0, Week 4, and Week 24</description>
    <arm_group_label>Engerix-B</arm_group_label>
    <other_name>Hepatitis B vaccine (recombinant)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        A subject must meet all of the following criteria to be eligible for the trial:

        Inclusion Criteria:

          -  Be 18-70 years of age, inclusive

          -  Able to comprehend and follow all required study procedures and be available for all
             visits scheduled in the study

          -  If a woman is of childbearing potential, she must consistently use an acceptable
             method of contraception or confirm in writing she will abstain from sexual activity
             from the Screening Visit through Week 28.

          -  Able and willing to provide informed consent

        A subject with any one of the following criteria is not eligible for the trial:

        Exclusion Criteria:

          -  Previous receipt of any hepatitis B vaccine

          -  History of hepatitis B or human immunodeficiency virus (HIV) infection or positive
             test for HBsAg, anti-HBs, antibody to hepatitis B core antigen (anti-HBc), or antibody
             to HIV

          -  History of autoimmune disorder

          -  History of sensitivity to any component of study vaccines

          -  Has received the following prior to the first injection:

               1. Within 28 days:

                    -  Any vaccine

                    -  Systemic corticosteroids (more than 3 consecutive days) or other
                       immunomodulators or immune suppressive medication

                    -  Granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage
                       colony-stimulating factor (GM-CSF)

                    -  Any other investigational medicinal agent

               2. Within 90 days: Blood products or immunoglobulin

               3. At any time: An injection of DNA plasmids or oligonucleotide

          -  If female: Pregnant, nursing, or planning to become pregnant during the trial

          -  Is undergoing chemotherapy or expected to receive chemotherapy during the study
             period; has a diagnosis of cancer within the last 5 years other than squamous or basal
             cell carcinoma of the skin

          -  Any other medical condition considered by the investigator likely to interfere with
             the subject's compliance or the interpretation of study assessments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Janssen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dynavax Technologies Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>83141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Elkhorn</city>
        <state>Nebraska</state>
        <zip>68022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <results_first_submitted>December 8, 2017</results_first_submitted>
  <results_first_submitted_qc>December 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 10, 2018</results_first_posted>
  <disposition_first_submitted>February 6, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>February 6, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 7, 2017</disposition_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBV vaccine</keyword>
  <keyword>HEPLISAV-B</keyword>
  <keyword>Hepatitis B vaccine</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>Hepatitis B virus (HBV)</keyword>
  <keyword>Prevention and Control</keyword>
  <keyword>Healthy</keyword>
  <keyword>Healthy volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HEPLISAV</title>
          <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
HEPLISAV and/or Placebo: Intramuscular (IM) injections at Week 0, Week 4, plus a placebo (saline) injection at Week 24</description>
        </group>
        <group group_id="P2">
          <title>Engerix-B</title>
          <description>1.0 mL Engerix-B
Engerix-B: Intramuscular injections at Week 0, Week 4, and Week 24</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5592"/>
                <participants group_id="P2" count="2782"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5092"/>
                <participants group_id="P2" count="2567"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
                <participants group_id="P2" count="215"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population: All subjects who received at least 1 study injection and who had any post-baseline safety data</population>
      <group_list>
        <group group_id="B1">
          <title>HEPLISAV</title>
          <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
HEPLISAV and/or Placebo: Intramuscular (IM) injections at Week 0, Week 4, plus a placebo (saline) injection at Week 24</description>
        </group>
        <group group_id="B2">
          <title>Engerix-B</title>
          <description>1.0 mL Engerix-B
Engerix-B: Intramuscular injections at Week 0, Week 4, and Week 24</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5587"/>
            <count group_id="B2" value="2781"/>
            <count group_id="B3" value="8368"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age ≥ 18 to ≤ 39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1132"/>
                    <measurement group_id="B2" value="561"/>
                    <measurement group_id="B3" value="1693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age ≥ 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4455"/>
                    <measurement group_id="B2" value="2220"/>
                    <measurement group_id="B3" value="6675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2743"/>
                    <measurement group_id="B2" value="1390"/>
                    <measurement group_id="B3" value="4133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2844"/>
                    <measurement group_id="B2" value="1391"/>
                    <measurement group_id="B3" value="4235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5587"/>
                    <measurement group_id="B2" value="2781"/>
                    <measurement group_id="B3" value="8368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of Special Interest</title>
        <description>The percentage of participants with Medically-attended adverse events (MAEs), Serious Adverse Events (SAEs), and immune-mediated Adverse Events of Special Interest (AESIs). MAEs are Adverse events (AEs) for which a subject sought medical attention at a doctor’s office, clinic or study site, or emergency room, or was hospitalized. SAEs are AEs that met the definition of Serious per FDA regulations. Immune-mediated AESIs are AEs that were confirmed to be autoimmune in etiology.</description>
        <time_frame>Week 56</time_frame>
        <population>Safety Population: All participants who received at least 1 study injection and who had any post-baseline safety data</population>
        <group_list>
          <group group_id="O1">
            <title>HEPLISAV</title>
            <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
HEPLISAV and/or Placebo: Intramuscular (IM) injections at Week 0, Week 4, plus a placebo (saline) injection at Week 24</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B</title>
            <description>1.0 mL Engerix-B
Engerix-B: Intramuscular injections at Week 0, Week 4, and Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of Special Interest</title>
          <description>The percentage of participants with Medically-attended adverse events (MAEs), Serious Adverse Events (SAEs), and immune-mediated Adverse Events of Special Interest (AESIs). MAEs are Adverse events (AEs) for which a subject sought medical attention at a doctor’s office, clinic or study site, or emergency room, or was hospitalized. SAEs are AEs that met the definition of Serious per FDA regulations. Immune-mediated AESIs are AEs that were confirmed to be autoimmune in etiology.</description>
          <population>Safety Population: All participants who received at least 1 study injection and who had any post-baseline safety data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5587"/>
                <count group_id="O2" value="2781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>New-onset Immune-mediated Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically-attended Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0"/>
                    <measurement group_id="O2" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2"/>
                    <measurement group_id="O2" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Type 2 Diabetes Mellitus Who Have a Seroprotective Immune Response</title>
        <description>Percentage of subjects with type 2 diabetes mellitus who have a seroprotective immune response (anti-HBs ≥ 10 milli-international unit (mIU)/mL) who receive HEPLISAV compared with subjects who receive Engerix-B</description>
        <time_frame>Week 28</time_frame>
        <population>Per-Protocol Diabetes Population:Randomized subjects with type 2 diabetes mellitus (clinical diagnosis of T2DM taking at least oral or non-insulin injectable hypoglycemic agent and/or insulin) who received all study injections, had no major protocol deviations, and had anti-HBs levels obtained within the study visit window at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>HEPLISAV</title>
            <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
HEPLISAV and/or Placebo: Intramuscular (IM) injections at Week 0, Week 4, plus a placebo (saline) injection at Week 24</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B</title>
            <description>1.0 mL Engerix-B
Engerix-B: Intramuscular injections at Week 0, Week 4, and Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Type 2 Diabetes Mellitus Who Have a Seroprotective Immune Response</title>
          <description>Percentage of subjects with type 2 diabetes mellitus who have a seroprotective immune response (anti-HBs ≥ 10 milli-international unit (mIU)/mL) who receive HEPLISAV compared with subjects who receive Engerix-B</description>
          <population>Per-Protocol Diabetes Population:Randomized subjects with type 2 diabetes mellitus (clinical diagnosis of T2DM taking at least oral or non-insulin injectable hypoglycemic agent and/or insulin) who received all study injections, had no major protocol deviations, and had anti-HBs levels obtained within the study visit window at Week 28.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="640"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="87.4" upper_limit="92.2"/>
                    <measurement group_id="O2" value="65.1" lower_limit="59.6" upper_limit="70.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through Week 56</time_frame>
      <desc>Adverse Events were assessed for the Safety Population: All participants who received at least 1 study injection and who had any post-baseline safety data.</desc>
      <group_list>
        <group group_id="E1">
          <title>HEPLISAV</title>
          <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
HEPLISAV and/or Placebo: Intramuscular (IM) injections at Week 0, Week 4, plus a placebo (saline) injection at Week 24</description>
        </group>
        <group group_id="E2">
          <title>Engerix-B</title>
          <description>1.0 mL Engerix-B
Engerix-B: Intramuscular injections at Week 0, Week 4, and Week 24</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="345" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Anaemia vitamin b12 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Ebstein's anomaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pituitary-dependent cushing's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Appendix disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cyclic vomiting syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Gastritis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Gastritis alcoholic haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hepatitis c</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Latent tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Mycobacterium avium complex infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Otitis media bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pneumonia escherichia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Splenic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Staphylococcal osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Viral sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Peripheral nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Procedural intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Traumatic haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Urinary retention postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrophoresis protein abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Foetal heart rate abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Brain neoplasm benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Ductal adenocarcinoma of pancreas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Intraductal papillary mucinous neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Ovarian cancer stage iii</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pelvic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage ii</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Carotid sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Radial nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Foetal growth restriction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Gestational diabetes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Oligohydramnios</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Placenta praevia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Bipolar i disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Substance-induced psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Bladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Diaphragmatic paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Diaphragmatic rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Victim of homicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1097" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="549" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="191" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="2781"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="5587"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="2781"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigator may communicate study results with prior written consent from Dynavax.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Janssen MD \ VP &amp; Chief Medical Officer</name_or_title>
      <organization>Dynavax Technologies, Inc.</organization>
      <phone>510-848-5100</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

